{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T07:45:59Z","timestamp":1759563959582},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,3,1]]},"DOI":"10.2169\/internalmedicine.2179-23","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T22:13:05Z","timestamp":1688508785000},"page":"717-720","source":"Crossref","is-referenced-by-count":6,"title":["High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation"],"prefix":"10.2169","volume":"63","author":[{"given":"Yasuhiro","family":"Uchida","sequence":"first","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Manabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Fukatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohito","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Koyama D, Kikuchi J, Kuroda Y, Ohta M, Furukawa Y. AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Sci 112: 194-204, 2020.","DOI":"10.1111\/cas.14698"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376: 917-927, 2017.","DOI":"10.1056\/NEJMoa1609324"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jabbour EJ, Sasaki K, Haddad FG, et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol 98: 658-665, 2023.","DOI":"10.1002\/ajh.26852"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543: 733-737, 2017.","DOI":"10.1038\/nature21702"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mauro MJ, Hughes TP, Kim DW, et al. Asciminib monotherapy in patients with CML-CP without <i>BCR::ABL1<\/i> T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia 37: 1048-1059, 2023.","DOI":"10.1038\/s41375-023-01860-w"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381: 2315-2326, 2019.","DOI":"10.1056\/NEJMoa1902328"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34: 966-984, 2020.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tran P, Hanna I, Eggimann FK, et al. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. Xenobiotica 50: 150-169, 2020.","DOI":"10.1080\/00498254.2019.1594449"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Imagawa J, Tanaka H, Okada M, et al.; the DADI Trial Group. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2: e528-e535, 2015.","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kimura S, Imagawa J, Murai K, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol 7: e218-e225, 2020.","DOI":"10.1016\/S2352-3026(19)30235-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Iurlo A, Cattaneo D, Consonni D, et al. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: updated results from a campus CML real-life study. Front Pharmacol 14: 1154377, 2023.","DOI":"10.3389\/fphar.2023.1154377"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Copland M. Is there a role for dose modification of TKI therapy in CML? Curr Hematol Malig Rep 14: 337-345, 2019.","DOI":"10.1007\/s11899-019-00524-w"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Iurlo A, Cattaneo D, Artuso S, et al. Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: a feasible option also in the real-life. A campus CML study. Front Oncol 12: 839915, 2022.","DOI":"10.3389\/fonc.2022.839915"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hoch M, Sato M, Zack J, et al. Pharmacokinetics of asciminib in individuals with hepatic or renal impairment. J Clin Pharmacol 61: 1454-1465, 2021.","DOI":"10.1002\/jcph.1926"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/5\/63_2179-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T03:38:21Z","timestamp":1709350701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/5\/63_2179-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2179-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"article-number":"2179-23"}}